Connect with us

Health

That’s all you need to know about the top candidates for the COVID-19 vaccine race

 


COVID-19 has infected 218 countries and territories worldwide, affecting 62.5 million people and killing 1.4 million people. As the second and third waves threaten further transmission, Researchers, pharmaceutical companies and pharmaceutical companies around the world are competing to find a cure for the coronavirus..

Currently, attention is focused on pharmaceutical companies that are working daily on the development, testing and manufacturing of the COVID-19 vaccine. The WHO report released earlier this month Currently, 48 vaccine candidates are undergoing clinical trials worldwide.

What should the vaccine deliver? WHO is willing to reduce it to 50% by the US Food and Drug Administration (USFDA), but wants at least 70% efficacy in trials. Meanwhile, the European Medicines Agency has suggested that it may accept lower efficacy levels.

Your story It provides an up-to-date list of popular vaccine candidates being tested, their current status, and where India stands in the vaccine competition.

COVID-19 vaccine

Typical image

National vaccine candidate

With the increasing number of cases of coronavirus in India Five companies are developing COVID-19 vaccine.. During a virtual meeting with the state government Prime Minister Narendra Modi “Five vaccine candidates are in the development stage in India, four in Phase II / III and one in Phase I / II trials.”

Vaccine candidates developed nationwide at an advanced stage are:

Bharat Biotech

Hyderabad base Bharat Biotech is developing Covaxin in collaboration with ICMR-National Institute of Virology (NIV).Vaccine candidates are currently in progress Phase III human study There are 26,000 participants. 1,000 subjects have successfully completed Phases I and II and have been reported to be safe with no serious adverse events.

“this Indigenous inactivated vaccine Developed and manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) biocontainment facility. COVAXIN ™ is a highly purified and inactivated vaccine manufactured on the Vero cell production platform. Safety record of more than 300 million doses“The company said in an official statement.

According to the report by India Today, Bharat Biotech’s vaccine candidates 60% effective against SAR-Cov-2 based on testing I’ve done it so far. The company aims to launch the vaccine by the second quarter of 2021.

price: Not announced

storage: 2 ° C to 8 ° C

Zydus Cadila

Apart from Bharat Biotech, the Government of India is also closely following Ahmedabad-based pharmaceutical company Zydus Cadila Vaccine Candidate ZyCov-D..

Earlier this month MoneyControl Revealed that the company has been completed Phase II trial This month, I was planning to submit the data to the Drug Administration (DCGI) in India. Zydus Plan to start Phase III trial There were about 15,000-20,000 participants in December.

The preliminary results did not raise any concerns.According to the report, Zydus candidates DNA vaccine Contains the genetic material of the COVID-19 virus. Instruct human cells to produce SARS-CoV2 Antigen-It provokes an immune response. The vaccine does not use live virus.

Zydus also recently announced that it was completed Phase II The biological therapy test, Pegylated interferon alpha-2b or “PegiHepTM” in 40 COVID-19 patients.

“”95 percent of subjects Those who received a single dose of PegiHepTM with standard treatment (SOC), It became virus-free by evaluation by RT-PCR. On day 14, significant clinical improvement was shown for patients in the reference group who received only SOC and only 68%. [of them] It showed improvement in clinical symptoms and became RT-PCR negative, “the company said in an official statement.

The company has revealed that PegiHepTM is not a new treatment. It was approved as a treatment for hepatitis C and was launched in the Indian market in 2011.

“We continue to consider safe and effective options for the treatment and management of COVID-19. Pegylated interferon alpha-2b has been shown to reduce viral titers when administered early in the disease, And we would like to explore this biological option further. We hope to enhance our treatment options to combat COVID-19. ” Cadila Healthcare Ltd, Managing Director, Dr Sharvil Patel In the statement.

price: Not announced

storage: 2 ° C to 8 ° C

Biological E

Biological E, a Hyderabad-based vaccine maker, announced earlier this month. Started Phase I and Phase II human clinical trials of COVID-19 subunit vaccine candidates In India after receiving approval from the Directorate General of Pharmaceutical Management (DGCI) of India.

This vaccine candidate is being developed in collaboration with the US-based Baylor College of Medicine and the US-based Dynavax Technologies Corporations.

“Phase I / II clinical trials of biological E Evaluate the safety and immunogenicity of vaccine candidates Approximately 360 healthy subjects between the ages of 18 and 65 consist of three dose levels of SARS-CoV-2 spike protein receptor-binding domains supplemented with CpG 1018 and alum, “the company said in a statement. Stated.

Vaccination schedule includes: Twice per participant And Administered every 28 days.. The results of this clinical trial will be published by February 2021.

price: Not announced

storage: Not announced

International vaccine candidate

Oxford-AstraZeneca

It is no exaggeration to say that the world has fixed their hopes. UK-based pharmaceutical company AstraZeneca and Oxford University Vaccine Candidate, AZD1222.

The company recently Phase III interim results From the UK and Brazil, it shows an average 70% effectiveness.

However, the results revealed that the efficacy of the vaccine differs between two different dosing regimens.The· Efficacy was 90 percent when the first dose was halved and the standard second dose was administered; Two complete doses showed 62 percent efficacy..

Both AstraZeneca and Oxford University Manufacturing error Preliminary results on why the group was initially given half the dose. But, surprisingly, this has resulted in higher potency.Media reports suggest The company will need to make additional attempts to clarify the data.

In india Oxford-AstraZeneca Vaccine Version, Covishield, It is being tested at the Serum Institute of India (SII), which is based in Pune.Media reports revealed that SII may have to do Additional testing For Covishield, we get approval to sell another version that may be more effective than the current version. This additional test is based on preliminary results for AZD1222.

In the official statement, SII is vaccine safe, Indian exams were on track.. “The Indian trials are proceeding smoothly with adherence to all necessary processes and protocols. So far, there are no concerns, but we are examining the available data and will make further statements if necessary. We are announcing, “says SII.

price: Not decided yet. Expected to be less than 1,000 rupees

storage: 2 ° C to 8 ° C

Pfizer and BioNTech

Global pharmaceutical companies Pfizer and BioNTech have completed their Phase III trials mRNA-based COVID-19 vaccine candidate BNT162b2..According to both companies, their vaccine candidates are 95% valid, Including adults 65 years and older.

The two companies said they had requested an emergency vaccine license (EUA) from the US Food and Drug Administration (FDA).

“The application in the United States represents an important milestone in our journey to bring the COVID-19 vaccine to the world, and we currently have a complete picture of both. Efficacy and safety profile of our vaccine, Gives confidence in that possibility.I’m looking forward to future plans Vaccine and related biologics advisory board discussions We will work closely with the FDA and regulators around the world to ensure vaccine candidate approval as quickly as possible. ” Dr. Albert Bourla, Chairman and Chief Executive Officer of Pfizer.

According to the official statement, the company Produce up to 50 million doses worldwide in 2020 And up to 1.3 billion doses by the end of 2021. However, the vaccine has not yet been approved for distribution anywhere in the world.

Federal Minister of India Harsh Dr. Valdan India reportedly may not need the Pfizer-BioNTech vaccine, as several other candidates have been reportedly tested. He said the company has nothing to do with India to manufacture the vaccine and needs to be approved and respond to its own country.

price: Reportedly $ 20 each

storage: -70 ° C

modern

On November 16th, U.S.-based biotechnology company Moderna announced that vaccine candidate mRNA-1273 94.5% valid against COVID-19According to preliminary data from the company’s ongoing Phase III clinical trials.

According to the company, mRNA-1273 An mRNA vaccine encoding a pre-fusion stabilized form of the spike (S) protein, Co-developed by Moderna and researchers at the NIAID Vaccine Research Center.

“Based on these interim safety and efficacy data, Moderna will submit an Emergency Use Permit (EUA) to the U.S. Food and Drug Administration (FDA) within the next few weeks and will submit it to the EUA. Final safety and efficacy data (Median duration is at least 2 months). Modana will also submit an application for approval to regulators around the world, “the company said in a statement.

price: The price is expected to be $ 37

storage: -20 ° C

Gamareya National Institute of Epidemiology and Microbiology

Vaccine Candidates of Russia-based National Institute of Epidemiology and Microbiology and Russian Direct Investment Fund (RDIF) Sputnik VIs the first COVID-19 vaccine registered in the country.Earlier this month, the institute announced that vaccine candidates had shown. 91.4% effectivenessIn response to the second interim analysis of the Phase III clinical trial.

“Preliminary data from volunteers obtained 42 days after the first dose (corresponding to 21 days after the second dose) show more than 95% vaccine efficacy,” said an official statement from Gamaleya and RDIF. I am.

According to the statement, the vaccine candidate is unique Use of two different vectors based on human adenovirusAllows for a stronger and longer-term immune response, compared to vaccines that use one and the same vector in two doses.

For RDIF Partnership with manufacturer In India, Brazil, South Korea, China and 4 other countries Vaccine manufacturing and distributionFollowing the announcement of the final results and approval.

RDIF has partnered with Indian pharmaceutical company Hetero to produce over 100 million Sputnik V doses. Every year in India. Production is scheduled to begin in 2021.

price: Russia is free.Less than $ 10 in the international market

storage: -18 ° C

Johnson & Johnson

October 23, Johnson & Johnson Pharmaceutical Division Janssen Announced plans to resume Phase III ENSEMBLE trial of vaccine candidates JNJ-78436735, also known as Ad26.COV2.S. The company is currently preparing to resume testing in the United States after consulting with the US FDA.

The company had to temporarily suspend the exam October 12, after one of the study participants was analyzed for an unexplained illness.However, after a thorough investigation was shown, the trial is now resumed. There is no evidence to prove that the vaccine candidate was the reason for the illness..

“After a thorough assessment of a serious medical event experienced by a research participant, no clear cause has been identified. There are many factors that could have caused the event,” Johnson and Johnson said in a statement. It is stated in.

The company has a data safety monitoring committee (DSMB) that oversees ENSEMBLE research. We recommend that you resume trial recruitment.

price: Likely to sell for $ 10

storage: 2 ° C to 8 ° C

..

What Are The Main Benefits Of Comparing Car Insurance Quotes Online

LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos



Pictures Credit

ExBUlletin

to request, modification Contact us at Here or [email protected]